A Study of ASN007 in Patients With Advanced Solid Tumors

Asana BioSciences

Status and phase: Completed; Phase 1

Conditions: Metastatic Nonsmall Cell Lung Cancer; Colon Cancer; Pancreas Cancer; Neoplasm Metastasis; Cancer; Metastatic Colon Cancer; Metastatic Lung Cancer; Metastatic Cancer; Neoplasm; Pancreas Adenocarcinoma; Non Small Cell Lung Cancer Metastatic; Colonic Neoplasms; Neoplasia; Metastatic Pancreatic Cancer; Metastatic Melanoma; Colon Cancer Liver Metastasis; Pancreas Neoplasm; Malignancy; Pancreatic Cancer

Treatments: Drug: ASN007: ascending doses; Drug: ASN007 RD

Study type: Interventional

Funder types: Industry

Identifiers

NCT03415126

ASN007-101

Details and patient eligibility

About

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

Full description

Part A is a dose escalation study to determine a safe and tolerable dose of ASN007 for patients with advanced solid tumors. Part A will also describe how the body works on ASN007(pharmacokinetics) and the effects of ASN007 on the body (pharmacodynamics) of ASN007, through blood sampling and optional biopsies..

Part B of the study will enroll patients with particular tumor types and genetic mutations for treatment at the Recommended Phase 2 Dose. Part B will enroll patients in five groups of fifteen patients each:

Group 1: Patients with metastatic BRAF mutated melanoma Group 2: Patients with metastatic NRAS and HRAS mutated solid tumors Group 3: Patients with metastatic KRAS mutated colorectal cancer (CRC) Group 4: Patients with metastatic KRAS mutated non-small cell lung cancer (NSCLC) Group 5: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Patients with melanoma will be required to have pre-dose and post-dose biopsies.

Group 6: Patients with metastatic MEK1, BRAF V600E, non-BRAF V600E solid tumors or BRAF fusions without prior treatment with BRAF, MEK, ERK inhibitors

Enrollment: 49 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent obtained prior to any study-related procedure being performed;
• Male or non-pregnant, non-lactating female patient at least 18 years of age at the time of consent;
• Eastern Cooperative Oncology Group Performance Status 0-1 (Part A) and PS 0-2 (Part B)
• Histologically or cytologically confirmed
• advanced or metastatic solid tumor (Part A)
• Group 1: BRAF mutant melanoma (Part B)
• Group 2: NRAS or HRAS mutant solid tumors(Part B)
• Group 3: KRAS mutant CRC.(Part B)
• Group 4: KRAS mutant NSCLC (Part B)
• Group 5: Pancreatic Ductal Adenocarcinoma (Part B)
• Progressive disease after failure of or intolerant to all available standard systemic treatments that have shown a documented benefit in overall survival for their respective tumor type.
• Measurable or evaluable disease per RECIST v1.1
• Screening hematology values of the following:
• absolute neutrophil count ≥ 1000/μL,
• platelets ≥ 100,000/μL,
• hemoglobin ≥ 9 g/dL
• Screening chemistry values of the following:
• alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3.0 × upper limit of the normal (ULN),
• total bilirubin ≤ 1.5 × ULN,
• creatinine ≤ 1.5 × ULN,,
• albumin ≥ 2.8 g/dL.
• Screening heart function lab test
• creatinine kinase - MB, troponin-I, and troponin-T within normal limits
• Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned.

Exclusion criteria

• Prior treatment with ASN007 or another ERK1/2 inhibitor
• Known hypersensitivity to ASN007 or its excipients;
• Part B: Prior treatment with a RAF or MEK pathway inhibitor, except BRAFmutant melanoma (Group 1)
• Prior chemotherapy, targeted therapy or monoclonal antibody therapy within 3 weeks of start of study treatment (Day1), or 5 half-lives, whichever is shorter.
• Concurrent or prior bone marrow factors (e.g. G-CSF, GM-CSF or erythropoietin) within 3 weeks prior to Day 1 of treatment.
• Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatment
• Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.
• History of or current evidence / risk of retinal vein occlusion (RVO) central serous retinopathy (CSR), or glaucoma with intraocular pressures ≥ 21 mmHg or other pre-existing ocular conditions that may put the patient at risk for ocular toxicities
• Known central nervous system (CNS) primary tumor, CNS metastases or carcinomatous meningitis (Part A). Patients may be enrolled with CNS metastasis in certain circumstances in Part B.
• Clinically significant heart disorders including an ejection fraction of < 50%
• Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,
• Any other condition that might place the patient at undue risk.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

49 participants in 7 patient groups

ASN007 ascending doses

Experimental group

Description:

Patients will receive escalating doses of ASN007 to identify the best dose.

Treatment:

Drug: ASN007: ascending doses

ASN007 RD: KRAS mutant Melanoma

Experimental group

Description:

Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.

Treatment:

Drug: ASN007 RD

ASN007 RD: NRAS mutant Melanoma

Experimental group

Description:

Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.

Treatment:

Drug: ASN007 RD

ASN007 RD: KRAS mutant metastatic CRC

Experimental group

Description:

Patients with KRAS mutant CRC will receive the recommended dose from Part A

Treatment:

Drug: ASN007 RD

ASN007 RD: KRAS mutant NSCLC

Experimental group

Description:

Patients with KRAS mutant NSCLC will receive the recommended dose from Part A

Treatment:

Drug: ASN007 RD

ASN007 RD: Metastatic Pancreatic Cancer

Experimental group

Description:

Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A

Treatment:

Drug: ASN007 RD

ASN007 RD: MEK, All BRAF, BRAF-fusion cancers

Experimental group

Description:

Patients with solid tumors will receive the recommended dose from Part A

Treatment:

Drug: ASN007 RD